We tested the feasibility of the PAC strategy on a panel of 12 human breast cancer cell lines that had been screened for mutations in seven tumor suppressor genes: BRCA1, CDH1, MAP2K4, PTEN, p16, p53 and RB1[14]–[18], and unpublished results). This evidence concerns the gene CDKN2A and breast cancer.